Deep phenotyping of the lipidomic response in COVID-19 and non-COVID-19 sepsis.
Journal
Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
15
09
2023
received:
20
06
2023
accepted:
01
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
ppublish
Résumé
Lipids may influence cellular penetrance by viral pathogens and the immune response that they evoke. We deeply phenotyped the lipidomic response to SARs-CoV-2 and compared that with infection with other pathogens in patients admitted with acute respiratory distress syndrome to an intensive care unit (ICU). Mass spectrometry was used to characterise lipids and relate them to proteins, peripheral cell immunotypes and disease severity. Circulating phospholipases (sPLA2, cPLA2 (PLA2G4A) and PLA2G2D) were elevated on admission in all ICU groups. Cyclooxygenase, lipoxygenase and epoxygenase products of arachidonic acid (AA) were elevated in all ICU groups compared with controls. sPLA2 predicted severity in COVID-19 and correlated with TxA2, LTE4 and the isoprostane, iPF2α-III, while PLA2G2D correlated with LTE4. The elevation in PGD2, like PGI2 and 12-HETE, exhibited relative specificity for COVID-19 and correlated with sPLA2 and the interleukin-13 receptor to drive lymphopenia, a marker of disease severity. Pro-inflammatory eicosanoids remained correlated with severity in COVID-19 28 days after admission. Amongst non-COVID ICU patients, elevations in 5- and 15-HETE and 9- and 13-HODE reflected viral rather than bacterial disease. Linoleic acid (LA) binds directly to SARS-CoV-2 and both LA and its di-HOME products reflected disease severity in COVID-19. In healthy marines, these lipids rose with seroconversion. Eicosanoids linked variably to the peripheral cellular immune response. PGE2, TxA2 and LTE4 correlated with T cell activation, as did PGD2 with non-B non-T cell activation. In COVID-19, LPS stimulated peripheral blood mononuclear cell PGF2α correlated with memory T cells, dendritic and NK cells while LA and DiHOMEs correlated with exhausted T cells. Three high abundance lipids - ChoE 18:3, LPC-O-16:0 and PC-O-30:0 - were altered specifically in COVID. LPC-O-16:0 was strongly correlated with T helper follicular cell activation and all three negatively correlated with multi-omic inflammatory pathways and disease severity. A broad based lipidomic storm is a predictor of poor prognosis in ARDS. Alterations in sPLA2, PGD2 and 12-HETE and the high abundance lipids, ChoE 18:3, LPC-O-16:0 and PC-O-30:0 exhibit relative specificity for COVID-19 amongst such patients and correlate with the inflammatory response to link to disease severity.
Sections du résumé
BACKGROUND
Lipids may influence cellular penetrance by viral pathogens and the immune response that they evoke. We deeply phenotyped the lipidomic response to SARs-CoV-2 and compared that with infection with other pathogens in patients admitted with acute respiratory distress syndrome to an intensive care unit (ICU).
METHODS
Mass spectrometry was used to characterise lipids and relate them to proteins, peripheral cell immunotypes and disease severity.
RESULTS
Circulating phospholipases (sPLA2, cPLA2 (PLA2G4A) and PLA2G2D) were elevated on admission in all ICU groups. Cyclooxygenase, lipoxygenase and epoxygenase products of arachidonic acid (AA) were elevated in all ICU groups compared with controls. sPLA2 predicted severity in COVID-19 and correlated with TxA2, LTE4 and the isoprostane, iPF2α-III, while PLA2G2D correlated with LTE4. The elevation in PGD2, like PGI2 and 12-HETE, exhibited relative specificity for COVID-19 and correlated with sPLA2 and the interleukin-13 receptor to drive lymphopenia, a marker of disease severity. Pro-inflammatory eicosanoids remained correlated with severity in COVID-19 28 days after admission. Amongst non-COVID ICU patients, elevations in 5- and 15-HETE and 9- and 13-HODE reflected viral rather than bacterial disease. Linoleic acid (LA) binds directly to SARS-CoV-2 and both LA and its di-HOME products reflected disease severity in COVID-19. In healthy marines, these lipids rose with seroconversion. Eicosanoids linked variably to the peripheral cellular immune response. PGE2, TxA2 and LTE4 correlated with T cell activation, as did PGD2 with non-B non-T cell activation. In COVID-19, LPS stimulated peripheral blood mononuclear cell PGF2α correlated with memory T cells, dendritic and NK cells while LA and DiHOMEs correlated with exhausted T cells. Three high abundance lipids - ChoE 18:3, LPC-O-16:0 and PC-O-30:0 - were altered specifically in COVID. LPC-O-16:0 was strongly correlated with T helper follicular cell activation and all three negatively correlated with multi-omic inflammatory pathways and disease severity.
CONCLUSIONS
A broad based lipidomic storm is a predictor of poor prognosis in ARDS. Alterations in sPLA2, PGD2 and 12-HETE and the high abundance lipids, ChoE 18:3, LPC-O-16:0 and PC-O-30:0 exhibit relative specificity for COVID-19 amongst such patients and correlate with the inflammatory response to link to disease severity.
Identifiants
pubmed: 37948331
doi: 10.1002/ctm2.1440
pmc: PMC10637636
doi:
Substances chimiques
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
59985-28-3
Leukotriene E4
75715-89-8
Prostaglandin D2
RXY07S6CZ2
Cyclooxygenase 2
EC 1.14.99.1
Eicosanoids
0
Phospholipases A2, Secretory
EC 3.1.1.4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1440Subventions
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Références
Theken KN, FitzGerald GA. Bioactive lipids in antiviral immunity. Science. 2021;371(6526):237-238.
Balgoma D, Gil-de-Gómez L, Montero O. Lipidomics issues on human positive ssRNA virus infection: an update. Metabolites. 2020;10(9):356.doi:10.3390/metabo10090356
Rattay S, Hufbauer M, Hoboth P, Sztacho M, Akgül B. Viruses and phospholipids: friends and foes during infection. J Med Virol. 2023;95(3):e28658. doi:10.1002/jmv.28658
Theken KN, Tang SY, Sengupta S, FitzGerald GA. The roles of lipids in SARS-CoV-2 viral replication and the host immune response. J Lipid Res. 2021;62:100129.
Monson EA, Trenerry AM, Laws JL, Mackenzie JM, Helbig KJ. Lipid droplets and lipid mediators in viral infection and immunity. FEMS Microbiol Rev. 2021;45(4):fuaa066.
Numata M, Voelker DR. Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(6):159139.
Beckmann N, Becker KA. Ceramide and related molecules in viral infections. Int J Mol Sci. 2021;22(11):5676.
Schneider-Schaulies S, Schumacher F, Wigger D, et al. Sphingolipids: effectors and achilles heals in viral infections. Cells. 2021;10(9):2175.
Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021;20(1):141.
Masana L, Correig E, Ibarretxe D, et al. STACOV-XULA research group. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep. 2021;11(1):7217.
Lipman D, Safo SE, Chekouo T. Multi-omic analysis reveals enriched pathways associated with COVID-19 and COVID-19 severity. PLoS One. 2022;17(4):e0267047.
Li Y, Hou G, Zhou H, et al. Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery. Signal Transduct Target Ther. 2021;6(1):155.
Li CX, Gao J, Zhang Z, et al. Multiomics integration-based molecular characterizations of COVID-19. 2022:bbab485.
Ciccarelli M, Merciai F, Carrizzo A, et al. Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy). J Pharm Biomed Anal. 2022;217:114827.
Song JW, Lam SM, Fan X, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab. 2020;32(2):188-202.
Giron LB, Dweep H, Yin X, et al. Plasma markers of disrupted gut permeability in severe COVID-19 patients. Front Immunol. 2021;12:686240. eCollection. doi:10.3389/fimmu.2021.686240
Torretta E, Garziano M, Poliseno M, et al. Severity of COVID-19 patients predicted by serum sphingolipids signature. Int J Mol Sci. 2021;22(19):10198.
Kurano M, Okamoto K, Jubishi D, et al. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. Clin Transl Med. 2022;12(10):e1069.
Wei J, Liu X, Xiao W, et al. Phospholipid remodeling and its derivatives are associated with COVID-19 severity. J Allergy Clin Immunol. 2023;151(5):1259-1268.
Kurano M, Jubishi D, Okamoto K, et al. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. J Biomed Sci. 2022;29(1):94.
Pérez MM, Pimentel VE, Fuzo CA, et al. ImmunoCOVID Brazilian Research Consortium. Acetylcholine, fatty acids, and lipid mediators are linked to COVID-19 severity. J Immunol. 2022;209(2):250-261.
Archambault AS, Zaid Y, Rakotoarivelo V, et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J. 2021;35(6):e21666.
Reina-Couto M, Roboredo-Madeira M, Pereira-Terra P, et al. Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients. Inflamm Res. 2023;72(3):475-491.
Bohnacker S, Hartung F, Henkel F, Quaranta A, et al. Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages. Mucosal Immunol. 2022;15(3):515-524.
Snider JM, You JK, Wang X, et al. Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality. J Clin Invest. 2021;131(19):e149236.
Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(2):158849.
Kashour T, Halwani R, Arabi YM, et al. Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. Immunopharmacol Immunotoxicol. 2021;43(1):37-50.
Tsareva NA, Avdeev SN, Kosanovic D, Schermuly RT, Trushenko NV, Nekludova GV. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit Care. 2021;25(1):258.
Funk CD, Ardakani A. A novel strategy to mitigate the hyperinflammatory response to COVID-19 by targeting leukotrienes. Front Pharmacol. 2020;11:1214.
Yasmeen N, Selvaraj H, Lakhawat SS, et al. Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators. Biochem Pharmacol. 2023;209:115437.
RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143-151.
FitzGerald GA. Misguided drug advice for COVID-19. Science. 2020;367(6485):1434.
Bange EM, Han NA, Wileyto P, et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27(7):1280-1289.
Laudanski K, Jihane H, Antalosky B, et al. Unbiased analysis of temporal changes in immune serum markers in acute COVID-19 infection with emphasis on organ failure, anti-viral treatment, and demographic characteristics. Front Immunol. 2021;12:650465.
Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511.
Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5(49):eabd7114.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Reilly JP, Meyer NJ, Shashaty G, et al. The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness. J Clin Invest. 2021;131(1):e139700.
Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100(6):1619-1636.
Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.
Siew ED, Ikizler TA, Matheny ME, et al. Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clin J Am Soc Nephrol. 2012;7(5):712-719.
Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intens Care Med. 2022;48(9):1144-1155.
Letizia AG, Ramos I, Obla A, et al. SARS-CoV-2 transmission among marine recruits during quarantine. N Engl J Med. 2020;383(25):2407-2416.
Balta MG, Papathanasiou E, Christopoulos PF. Specialized pro-resolving mediators as potential regulators of inflammatory macrophage responses in COVID-19. Front Immunol. 2021;12:632238.
Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA. 2003;100:1393-1398.
Sengupta A, Weljie AM, NMR Spectroscopy-based metabolic profiling of biospecimens. Cur Prot Protein Sci. 2019;98(1):e98.
Bemis KD, Harry A, Eberlin LS, et al. Cardinal: an R package for statistical analysis of mass spectrometry-based imaging experiments. Bioinformatics. 2015;31(14):2418-2420.
Smets T, Waelkens E, De Moor B. Prioritization of m/z-values in mass spectrometry imaging profiles obtained using uniform manifold approximation and projection for dimensionality reduction. Anal Chem. 2020;92(7):240-5248.
Bemis KD, Harry A, Eberlin LS, et al. Cardinal: an R package for statistical analysis of mass spectrometry-based imaging experiments. Bioinformatics. 2015;31(14):2418-2420. doi:10.1093/bioinformatics/btv146
Cosgriff CV, Miano TA, Mathew D, et al. Validating a proteomic signature of severe COVID-19. Crit Care Explor. 2022;4(12):e0800.
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613.
McReynolds CB, Cortes-PuchI RR, KhanIH HBG, Shih P-AB, HammockBD YJ. Plasma linoleate diols are potential biomarkers for severe COVID-19 infections. Front Physiol. 2021;12:663869.
Gupta PK, Godec J, Wolski D, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 2015;11(10):e1005177. doi:10.1371/journal.ppat.1005177
Hao Y, Zhang Z, Feng G, et al. Distinct lipid metabolic dysregulation in asymptomatic COVID-19. iScience. 2021;24(9):102974.
Castro-Perez JM, Kamphorst J, DeGroot J, et al. Comprehensive LC−MSE lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J Proteome Res. 2010;9(5):2377-2389.
Dobi A, Dubernet A, Rakoto ML, et al. Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels. Immunol Res. 2022;70:714-719.
Shen Y, Wang J, Li Y, et al. Structures of ACE2-SIT1 recognized by Omicron variants of SARS-CoV-2. Cell Discov. 2022;8:123.
Rebendenne A, Roy P, Bonaventure B, et al. Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HcoVs. Nat Genet. 2022;54:1090-1102.
Baggen J, Persoons L, Vanstreels E, et al. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat Genet. 2021;53(61):435-444.
Toelzer C, Gupta K, Yadav SKN, et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science. 2020;370(6517):725-730.
Grosser T, Naji A, FitzGerald GA. Urinary prostaglandin metabolites: an incomplete reckoning and a flush to judgment. Circ Res. 2018;122(4):537-539.
Tan TL, Goh YY. The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-a systematic review. PLoS ONE. 2017;12(7):e0180554.
Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99(9):2118-2127.
Lam SM, Zhang C, Wang Z, et al. A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19. Nat Metab. 2021;3(7):909-922.
Song J-W, Lam SM, Fan X, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab. 2020;32(2):188-202.
Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD2 expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121(12):4921-4930.
Werder RB, Lynch JP, Simpson JC, et al. PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN- λ production. Sci Transl Med. 2018;10(440):eaao0052.
Wong L-YR, Zheng J, Wilhelmsen K, et al. Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19. Nature. 2022;605(7908):146-151.
Oga T, Matsuoka T, Yao C, et al. Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med. 2009;15(12):1426-1430.
Stewart I, Jacob J, George PM, et al. Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post-COVID-19 study. Am J Respir Crit Care Med. 2023;207(6):693-703.